# Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort

> **NCT07336836** · EARLY_PHASE1 · COMPLETED · sponsor: **BioNADrx Holdings, Inc. Bryleos** · enrollment: 60 (actual)

## Conditions studied

- Health Adult Subjects
- Healthy Participants

## Interventions

- **DIETARY_SUPPLEMENT:** LathMized TM NAD+ (LNAD+)
- **OTHER:** Control (placebo)

## Key facts

- **NCT ID:** NCT07336836
- **Lead sponsor:** BioNADrx Holdings, Inc. Bryleos
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-23
- **Primary completion:** 2022-06-04
- **Final completion:** 2022-06-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07336836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07336836, "Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07336836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*